Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis

VernacularTitle:非酒精性脂肪肝病的治疗模式和潜在疗法
Author: Feng LI ¹ ; Maowei LI ² ; Yushan WANG ³
Author Information

1. Office of Clinical Trial Institutions for Drug and Medical Devices， The FAW General Hospital of Jilin Province， Changchun 130000， China
2. Department of Pharmacy， The Second Hospital of Changchun， Changchun 130000， China
3. Department of Drug Management， The FAW General Hospital of Jilin Province， Changchun 130000， China
Publication Type:Review
Keywords: Non-alcoholic Fatty Liver Disease; Fatty Liver; Therapeutics
From: Journal of Clinical Hepatology 2024;40(10):2082-2086
CountryChina
Language:Chinese
Abstract: In recent years， steady progress has been made in the epidemiology， pathogenesis， and therapeutic targets of nonalcoholic steatohepatitis （NASH）， while there has been slow progress in the field of therapeutic drug development. This article reviews the advances in lifestyle intervention， surgical methods， gut microbiota， and drugs in the treatment of NASH， especially the role of insulin sensitizers， antioxidants， cholesterol-lowering drugs， thyroid hormone mimetics， incretins， and cytokines in the treatment of NASH， in order to provide more methods and options for the treatment of NASH in the future.